Form 4: Silo Pharma Director Kevin Munoz Granted 50,000 Stock Options Under Equity Incentive Plan

Silo Pharma, Inc. Director Kevin Munoz was granted 50,000 stock options with an exercise price of $0.429, vesting in one year, as part of the company's 2020 Omnibus Equity Incentive Plan.

Summary

• Kevin Munoz, a Director of Silo Pharma, Inc. (SILO), was granted 50,000 stock options on May 23, 2025.
• The options have an exercise price of $0.429 per share.
• These options were issued under the Issuer's 2020 Omnibus Equity Incentive Plan.
• One hundred percent (100%) of the shares subject to the option will vest on May 23, 2026, which is the one-year anniversary of the grant date.
• The options have an expiration date of May 23, 2035.
• Following this transaction, Kevin Munoz beneficially owns 53,425 derivative securities (options).

Sentiment

Score: 6

Explanation: Slightly positive, as it indicates alignment of management interests with shareholders through equity compensation, which is a standard and generally well-regarded practice.

Positives

• The grant of stock options aligns the interests of Director Kevin Munoz with those of the shareholders, incentivizing long-term company performance.
• The transaction is part of a pre-existing and approved 2020 Omnibus Equity Incentive Plan, indicating a structured approach to executive compensation.

Future Outlook

The options granted to Director Kevin Munoz are set to vest on May 23, 2026, which will allow him to exercise them if the stock price is above the exercise price of $0.429.

Industry Context

The granting of stock options to directors and executives is a common practice across various industries, including the pharmaceutical sector, to attract, retain, and incentivize key personnel by linking their compensation to the company's stock performance.

Comparison to Industry Standards

• The use of an Omnibus Equity Incentive Plan for granting options is a standard corporate governance practice for publicly traded companies, aligning with typical compensation structures seen in the biotechnology and pharmaceutical industries.
• The vesting schedule of one year is a common period for initial grants, balancing immediate incentive with long-term commitment, comparable to practices at similar-sized biotech firms.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's financial interests with shareholder value, potentially leading to better long-term performance.
• Management/Directors: Provides an incentive for the director to contribute to the company's growth and stock appreciation.

Next Steps

• The options will vest on May 23, 2026, at which point Kevin Munoz will be able to exercise them.

Key Dates

Keywords

Silo Pharma, SILO, stock options, equity incentive plan, insider transaction, Form 4, director compensation, beneficial ownership